Licence details
Novotech Australia Pty Ltd
Human adenovirus
Deletions with E1A gene to limit replication, replacement of the hexon hypervariable region with that from another strain, replacement of E3 gene with human CD40L
This licence allows Novotech (Australia) Pty Ltd to conduct a clinical trial of a genetically modified (GM) human adenovirus for treatment of melanoma in Australia.
The GM treatment is based on human adenovirus, which can cause respiratory illness in some people. It has been modified by deleting parts of several genes, so that it multiplies in and then kills cancerous tumour cells with limited effects on healthy cells. One gene has also been introduced into the GM treatment that stimulates the body’s immune system to recognise and kill tumour cells.
The GMO will be manufactured overseas and imported into Australia. Up to 30 patients with metastatic melanoma will receive the GMO at clinical trial sites and hospitals in Australia, over a period of 3 years.
The RARMP concluded that the clinical trial poses negligible risks to people or the environment. However, as this is a clinical trial under limited and controlled conditions, licence conditions have been imposed to:
- restrict when and where the trial can take place
- limit the size of the trial
- restrict the spread and persistence of the GMO.
The risk analysis for this application was carried out in accordance with the Regulator’s Risk Analysis Framework.
Documents
Outlines the Regulator’s decision to issue a licence following the assessment of this application.
FAQs on the licence application and the Regulator’s decision to issue a licence for this application.
A summary of the Risk Assessment and Risk Management Plan prepared as part of the assessment of this application. It provides a brief description of the licence application, the risk assessment and risk management plan.
The final risk assessment and management plan prepared to support the Regulator's decision. It describes the GMO(s) and proposed work with the GMO(s) and provides an assessment of potential risks posed by the GMO(s). It also includes a summary of submissions received during the public consultation process.
Sets out the licence conditions imposed by the Regulator, including the licence holder’s general and specific obligations and reporting requirements.